Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2005 to 2009 of 2009 entries
Sorted by: Best Match Show Resources per page
Cyclosporine A to Treat Unexplained Recurrent Spontaneous Abortions: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial.

International journal of women's health

Wang N, Ge H, Zhou S.
PMID: 34916855
Int J Womens Health. 2021 Dec 10;13:1243-1250. doi: 10.2147/IJWH.S330921. eCollection 2021.

BACKGROUND: The World Health Organization (WHO) has defined Unexplained Recurrent Spontaneous Abortion (URSA) as three and more consecutive miscarriages before the 20th week of gestation. To date, empiric therapy for patients with unexplained recurrent pregnancy loss (URPL) is not...

Cite
Wang N, Ge H, Zhou S. Cyclosporine A to Treat Unexplained Recurrent Spontaneous Abortions: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. Int J Womens Health. 2021;13:1243-1250doi: 10.2147/IJWH.S330921.
Wang, N., Ge, H., & Zhou, S. (2021). Cyclosporine A to Treat Unexplained Recurrent Spontaneous Abortions: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. International journal of women's health, 131243-1250. https://doi.org/10.2147/IJWH.S330921
Wang, Nan, et al. "Cyclosporine A to Treat Unexplained Recurrent Spontaneous Abortions: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial." International journal of women's health vol. 13 (2021): 1243-1250. doi: https://doi.org/10.2147/IJWH.S330921
Wang N, Ge H, Zhou S. Cyclosporine A to Treat Unexplained Recurrent Spontaneous Abortions: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. Int J Womens Health. 2021 Dec 10;13:1243-1250. doi: 10.2147/IJWH.S330921. eCollection 2021. PMID: 34916855; PMCID: PMC8670855.
Copy Download .nbib Format: NLM
[Clinical profile of patients with chronic urticaria in a tertiary care hospital of the social security system in Costa Ricas].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)

Sedó-Mejía G, Lotz-Esquivel S, Monge-Ortega OP, Pino-García C.
PMID: 34904558
Rev Alerg Mex. 2021 Oct-Dec;68(4):225-232. doi: 10.29262/ram.v68i4.881.

OBJECTIVE: To describe the medical and laboratory profile of the patients who have been diagnosed with chronic urticaria in the outpatient clinic of a tertiary care hospital of the social security system in Costa Rica.METHODS: All patients over 13...

Cite
Sedó-Mejía G, Lotz-Esquivel S, Monge-Ortega OP, et al. Perfil clínico de los pacientes con urticaria crónica en un hospital de tercer nivel de atención del sistema de seguridad social de Costa Rica. [Clinical profile of patients with chronic urticaria in a tertiary care hospital of the social security system in Costa Ricas]. Rev Alerg Mex. 2021;68(4):225-232doi: 10.29262/ram.v68i4.881.
Sedó-Mejía, G., Lotz-Esquivel, S., Monge-Ortega, O. P., & Pino-García, C. (2021). Perfil clínico de los pacientes con urticaria crónica en un hospital de tercer nivel de atención del sistema de seguridad social de Costa Rica. [Clinical profile of patients with chronic urticaria in a tertiary care hospital of the social security system in Costa Ricas]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 68(4), 225-232. https://doi.org/10.29262/ram.v68i4.881
Sedó-Mejía, Giovanni, et al. "Perfil clínico de los pacientes con urticaria crónica en un hospital de tercer nivel de atención del sistema de seguridad social de Costa Rica." [Clinical profile of patients with chronic urticaria in a tertiary care hospital of the social security system in Costa Ricas]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) vol. 68,4 (2021): 225-232. doi: https://doi.org/10.29262/ram.v68i4.881
Sedó-Mejía G, Lotz-Esquivel S, Monge-Ortega OP, Pino-García C. Perfil clínico de los pacientes con urticaria crónica en un hospital de tercer nivel de atención del sistema de seguridad social de Costa Rica. [Clinical profile of patients with chronic urticaria in a tertiary care hospital of the social security system in Costa Ricas]. Rev Alerg Mex. 2021 Oct-Dec;68(4):225-232. doi: 10.29262/ram.v68i4.881. Spanish. PMID: 34904558.
Copy Download .nbib Format: NLM
Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia.

Journal of clinical laboratory analysis

Wang T, He X, Ran N, Liu C, Xing L, Wang H, Fu R, Shao Z.
PMID: 34329516
J Clin Lab Anal. 2021 Sep;35(9):e23922. doi: 10.1002/jcla.23922. Epub 2021 Jul 30.

OBJECTIVE: Immune thrombocytopenia (ITP) is well-known as an antibody-mediated autoimmune disease, and it is easy to get response but often turns to relapse or refractory. Cyclosporin is a traditional immunosuppressant and had a good effect on ITP patients. In...

Cite
Wang T, He X, Ran N, et al. Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. J Clin Lab Anal. 2021;35(9):e23922doi: 10.1002/jcla.23922.
Wang, T., He, X., Ran, N., Liu, C., Xing, L., Wang, H., Fu, R., & Shao, Z. (2021). Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. Journal of clinical laboratory analysis, 35(9), e23922. https://doi.org/10.1002/jcla.23922
Wang, Ting, et al. "Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia." Journal of clinical laboratory analysis vol. 35,9 (2021): e23922. doi: https://doi.org/10.1002/jcla.23922
Wang T, He X, Ran N, Liu C, Xing L, Wang H, Fu R, Shao Z. Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. J Clin Lab Anal. 2021 Sep;35(9):e23922. doi: 10.1002/jcla.23922. Epub 2021 Jul 30. PMID: 34329516; PMCID: PMC8418498.
Copy Download .nbib Format: NLM
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.

Clinical pharmacology : advances and applications

Nanda K, Moss AC.
PMID: 22888278
Clin Pharmacol. 2012;4:41-50. doi: 10.2147/CPAA.S26556. Epub 2012 Jul 25.

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce...

Cite
Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol. 2012;4:41-50doi: 10.2147/CPAA.S26556.
Nanda, K., & Moss, A. C. (2012). Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clinical pharmacology : advances and applications, 441-50. https://doi.org/10.2147/CPAA.S26556
Nanda, Kavinderjit, and Moss, Alan C. "Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine." Clinical pharmacology : advances and applications vol. 4 (2012): 41-50. doi: https://doi.org/10.2147/CPAA.S26556
Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol. 2012;4:41-50. doi: 10.2147/CPAA.S26556. Epub 2012 Jul 25. PMID: 22888278; PMCID: PMC3413022.
Copy Download .nbib Format: NLM
Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A.

Journal of transplantation

Tang L, Azzi J, Kwon M, Mounayar M, Tong R, Yin Q, Moore R, Skartsis N, Fan TM, Abdi R, Cheng J.
PMID: 22545201
J Transplant. 2012;2012:896141. doi: 10.1155/2012/896141. Epub 2012 Mar 29.

We encapsulated cyclosporine A (CsA) in poly(ethylene glycol)-b-poly(d,l-lactide-co-glycolide) (PEG-PLGA) nanoparticles (NPs) by nanoprecipitation of CsA and PEG-PLGA. The resulting CsA/PEG-PLGA-NPs were

Cite
Tang L, Azzi J, Kwon M, et al. Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A. J Transplant. 2012;2012:896141doi: 10.1155/2012/896141.
Tang, L., Azzi, J., Kwon, M., Mounayar, M., Tong, R., Yin, Q., Moore, R., Skartsis, N., Fan, T. M., Abdi, R., & Cheng, J. (2012). Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A. Journal of transplantation, 2012896141. https://doi.org/10.1155/2012/896141
Tang, Li, et al. "Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A." Journal of transplantation vol. 2012 (2012): 896141. doi: https://doi.org/10.1155/2012/896141
Tang L, Azzi J, Kwon M, Mounayar M, Tong R, Yin Q, Moore R, Skartsis N, Fan TM, Abdi R, Cheng J. Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A. J Transplant. 2012;2012:896141. doi: 10.1155/2012/896141. Epub 2012 Mar 29. PMID: 22545201; PMCID: PMC3321582.
Copy Download .nbib Format: NLM
Showing 2005 to 2009 of 2009 entries